These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 22336671)

  • 1. HDAC modulation and cell death in the clinic.
    Dell'Aversana C; Lepore I; Altucci L
    Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic alterations and cancer: new targets for therapy.
    Allen A
    IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
    Richon VM
    Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
    Emanuele S; Lauricella M; Tesoriere G
    Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
    Hanikoglu A; Hanikoglu F; Ozben T
    Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy.
    Ahmad M; Hamid A; Hussain A; Majeed R; Qurishi Y; Bhat JA; Najar RA; Qazi AK; Zargar MA; Singh SK; Saxena AK
    DNA Cell Biol; 2012 Oct; 31 Suppl 1():S62-71. PubMed ID: 22462686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylation of proteins as novel target for antitumor therapy: review article.
    Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
    Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of HDAC inhibitors].
    Sowa Y
    Gan To Kagaku Ryoho; 2010 Sep; 37(9):1665-8. PubMed ID: 20841929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDAC inhibitors for the treatment of cancer.
    Secrist JP; Zhou X; Richon VM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
    Jazirehi AR
    Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic regulation of airway inflammation.
    Adcock IM; Tsaprouni L; Bhavsar P; Ito K
    Curr Opin Immunol; 2007 Dec; 19(6):694-700. PubMed ID: 17720468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
    Bai Y; Ahmad D; Wang T; Cui G; Li W
    Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting histone deacetylase in thyroid cancer.
    Russo D; Durante C; Bulotta S; Puppin C; Puxeddu E; Filetti S; Damante G
    Expert Opin Ther Targets; 2013 Feb; 17(2):179-93. PubMed ID: 23234477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of HDAC inhibitors as cognitive enhancers.
    Gräff J; Tsai LH
    Annu Rev Pharmacol Toxicol; 2013; 53():311-30. PubMed ID: 23294310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
    Rangwala S; Zhang C; Duvic M
    Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of histone deacetylase inhibitors in the treatment of cancer (Review).
    Mei S; Ho AD; Mahlknecht U
    Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.
    Johnstone RW
    Nat Rev Drug Discov; 2002 Apr; 1(4):287-99. PubMed ID: 12120280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.